Silexion Therapeutics Corp
Developing a local drug delivery platform to treat KRAS-driven cancers and solid tumors.
SLXN | US
Overview
Corporate Details
- ISIN(s):
- KYG1281K1141 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 12 ABBA HILLEL ROAD, 5250606 RAMAT GAN
- Website:
- https://www.moringaac.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers and other solid tumors, such as pancreatic cancer. The company's core technology is its proprietary LODER (Local Drug Eluter) drug delivery platform. This platform is designed to provide local and prolonged delivery of therapeutic agents directly within the tumor core, aiming to solve significant drug delivery challenges and improve outcomes for patients with hard-to-treat cancers. Silexion is also developing innovative RNA-based therapeutics and collaborates with industry partners to advance its clinical manufacturing and formulation development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Silexion Therapeutics Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Silexion Therapeutics Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Silexion Therapeutics Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
